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IntrODuctIOn
O ral squamous cell carcinoma is the sixth most common neoplasm worldwide, with more than half a million new cases being diagnosed annually (Parkin et al., 2005; Allen et al., 2007) , particularly in certain areas of Asia, the Pacific Islands, Europe, and Brazil, where it constitutes up to one-quarter of all human cancers (Funk et al., 2002; Jemal et al., 2004) . Unfortunately, survival of oral squamous cell carcinoma patients has not been significantly improved, despite recent advances in chemotherapy and radiotherapy (Davies and Welch, 2006) . It is therefore imperative that we understand the underlying molecular mechanisms during the pathogenesis of oral squamous cell carcinoma and discover novel therapeutic targets for the prevention and treatment of this devastating disease.
The nuclear factor-κB (NF-κB) family of transcription factors includes p105/p50 (NF-κB1), p100/p52 (NF-κB2), p65 (RelA), RelB, and c-Rel, among which the p50/p65 heterodimer is most abundant (Li and Verma, 2002; Hayden and Ghosh, 2008) . The p50/p65 heterodimer is localized in the cytoplasm, where it binds to IκB inhibitory proteins, including IκBα, IκBβ, and IκBε. Upon stimulation, IκB proteins are rapidly phosphorylated by I-κB kinase α and β (IKKα and IKKβ) and are degraded via the ubiquitinproteasome pathway (Shishodia and Aggarwal, 2004) . Degradation of IκB proteins exposes the nuclear localization signals on the p50/p65 heterodimer, which then translocates to the nucleus for transcriptional up-regulation of a variety of downstream genes that govern innate immunity, inflammation, cell growth, and apoptosis (Gupta et al., 2010) . Notably, p65 phosphorylation by both IKKα and β is critically required for its liberation from the IKK complex during NF-κB activation (Sizemore et al., 2002) .
Andrographolide (Andro) is a diterpenoid lactone isolated from a plant called Andrographis paniculata, which has been used widely as a regimen of traditional herbal medicine for amelioration of sore throat, diarrhea, and other inflammatory disorders in Asian countries for more than two millennia. Recently, Andro has been shown to inhibit the in vitro cell growth of hepatocellular carcinoma (Zhou et al., 2006) , cervical carcinoma (Rajagopal et al., 2003) , prostatic adenocarcinoma (Kim et al., 2005) , and colorectal carcinoma (Kumar et al., 2004) . Mechanistically, Andro is known to induce apoptosis of human cancer cells via the death-receptor-mediated apoptotic pathway (Rajagopal et al., 2003) . It also sensitizes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in TRAIL-resistant human cancer cells (Zhou et al., 2008) . In addition, Andro affects the activity Andrographolide Inhibits Oral squamous cell carcinogenesis through nF-κb Inactivation of CDK P cdc2 and induces the expression of cell-cycle inhibitor P27 for restraining tumor cells at G 0 /G 1 (Zhou et al., 2006) . By suppressing the ERK1/2 pathway, it reportedly induces TNF-α synthesis and stimulates production of cytotoxic T-lymphocytes for the inhibition of tumor growth in vivo (Qin et al., 2006) . Furthermore, Andro inhibits tumor-induced angiogenesis by decreasing the expression of vascular endothelial growth factor (VEGF), nitric oxide (NO), and various inflammatory cytokines and chemokines while increasing the expression of endogenous anti-angiogenesis factors, such as interleukin (IL)-2 and tissue inhibitors of metalloproteinase-1 (TIMP-1; Sheeja et al., 2007) . However, the biochemical mechanisms of how Andro inhibits cancers are still largely unknown. Notably, many chemically diverse substances from natural sources, especially foods, have been shown to target various steps in carcinogenesis, including survival, proliferation, apoptosis, angiogenesis, invasion, and metastasis of tumor cells (Gupta et al., 2010) .
In previous studies, we have shown that Andro covalently modifies reduced cysteine 62 in the oligonucleotide binding pocket of p50 for inhibition of NF-κB activation in inflammation (Xia et al., 2004) , arterial restenosis (Wang et al., 2007) , and deep vein thrombosis (Li et al., 2009) . Importantly, aberrant NF-κB activation, which critically mediates cell proliferation and prevents cell apoptosis (Deveraux et al., 1998) , has been detected in a variety of human cancers, such as prostate carcinoma (Paule et al., 2007) , esophageal carcinoma (Yamada et al., 2007) , breast carcinoma (Ahmed et al., 2006) , intestinal carcinoma (Stark et al., 2007) , and oral carcinoma (Allen et al., 2007; Garg et al., 2008) . Given the observed inhibitory activity of Andro on the NF-κB signal transduction pathway, we speculated whether Andro could inhibit carcinogenesis through targeting p50 and consequently inactivating NF-κB signaling. In this study, we tested this hypothesis using the hamster buccal pouch model of DMBA-induced squamous cell carcinoma and the human cell line of tongue squamous cell carcinoma Tb cells.
MAtErIAls & MEthODs
For complete information, please see the online Appendix.
rEsults

nF-κb Activation in squamous cell carcinoma
Phosphorylation of p65 (Ser536) and IκBα (Ser32/36) reportedly indicates NF-κB activation, while c-Myc and cyclin D1 are wellknown NF-κB downstream targeting molecules (Li and Verma, 2002; Zhang et al., 2005; Allen et al., 2007; Hayden and Ghosh, 2008) . To determine whether chemically induced oral squamous cell carcinogenesis could elicit aberrant NF-κB activation, we examined total p65, p65 (Ser536), and IκBα (Ser32/36) phosphorylation and c-Myc and cyclin D1 expression at various stages of DMBA-induced squamous cell carcinogenesis in the hamster buccal pouch model. According to the guidelines of WHO classification, tissue samples stained with H&E were classified into the stages of normal mucosa, hyperplasia, dysplasia, carcinoma in situ, and carcinoma ( Fig. 1 and Appendix Table) . Total p65, phosphorylated p65 (Ser536), and IκBα (Ser32/36) were not detected at the stages of normal mucosa and hyperplasia. However, total p65, phosphorylated p65 (Ser536), and IκBα (Ser32/36) were clearly visible at the stage of dysplasia, further increased at the stage of carcinoma in situ, and peaked at the stage of carcinoma. Notably, phosphorylated 65 (Ser536) was restricted in the cytoplasm at stages of dysplasia and carcinoma in situ, whereas it was localized in both the cytoplasm and nucleus at the stage of carcinoma. In contrast, phosphorylated IκBα (Ser32/36) was distributed exclusively in the cytoplasm. Consistently, the expression of cytoplasmic and nuclear c-Myc and nuclear cyclin D1 was not detected until the stage of hyperplasia, and gradually intensified at the stages of dysplasia and carcinoma in situ, finally peaking at the stage of carcinoma. These results clearly indicated that DMBA-induced oral squamous cell carcinogenesis triggers aberrant NF-κB activation, especially in the pathological stages of dysplasia, carcinoma in situ, and carcinoma.
Andro Inhibits Oral squamous cell carcinoma
We have previously shown that Andro covalently modifies reduced cysteine 62 in the κB binding pocket of p50, which drastically diminishes NF-κB activation (Xia et al., 2004) . To elucidate whether NF-κB activation critically participates in the pathogenesis of chemically induced squamous cell carcinoma, we tested whether Andro could inhibit DMBA-induced oral squamous cell carcinogenesis. Intraperitoneal treatment with Andro, but not saline (blank) or 4H-Andro (an inactive structural analog), drastically switched the appearance of almost all tumors from papillary protuberance (ulcerative, erosive, reddish, and fragile with micro-hemorrhage) into smooth, pale, and encapsulated tissue masses, with concomitant amelioration of edema and hyperemia in the neighboring tissues around cancerous lesions ( Fig. 2A, left panel) . Most importantly, Andro, but not 4H-Andro, potently reduced tumor volumes ( Fig. 2A,  right panel) . Notably, no significant differences in the infiltrated leukocytes, including neutrophils and macrophages, were detected in the serial sections of tumor samples that had been treated with Andro, saline, and 4H-Andro (Fig. 2B) , thus eliminating the possibility that Andro might affect leukocyte deposition within these cancerous tissues. These findings attested to the functional significance of NF-κB activation during the pathogenesis of DMBA-induced oral squamous cell carcinoma. Consequently, Andro, but not 4H-Andro, decreased BrdU staining of DNA incorporation (Fig. 2C) and increased Tunel staining of DNA fragmentation (Fig. 2D ) of neoplastic tissues, which were markers for cell proliferation and apoptosis, respectively. Using the vWF antigen as a marker for vascular endothelial cells, we found that Andro, but not 4H-Andro, also diminished the formation of neovasculatures within the malignant tissues ( Fig. 2E ).
Andro suppresses Aberrant nF-κb Activation
We next tested whether Andro indeed prevented NF-κB activation of oral squamous cell carcinoma through targeting p50. As predicted, Andro significantly reduced the expression of total p65 (Fig. 3A) , phosphorylated p65 (Ser536) (Fig. 3B ), IκBα (Ser32/36) (Fig. 3C ), c-Myc (Fig. 3D) , and cyclin D1 (Fig. 3E ) in tumor tissues as compared with 4H-Andro. These results convincingly demonstrate that Andro inhibits aberrant NF-κB activation of chemically induced oral squamous cell carcinoma. Analysis of these data, taken together, suggests that Andro exerts its anti-cancer action by attenuating NF-κB activation, suppressing tumor cell proliferation, promoting tumor cell apoptosis, and preventing tumor-induced angiogenesis through targeting NF-κB transcription factor p50.
Effects of Andro on nF-κb Activation and survival of tb cells
In an effort to correlate our findings obtained from using the hamster model of chemically induced squamous cell carcinogenesis with human cancers, we tested the actions of Andro on human tongue squamous cell carcinoma Tb cells. Indeed, treat-ment with Andro, but not DMSO, reduced the expression of total p65, phosphorylated p65 (Ser536), c-Myc, and cyclin D1 in a concentration-dependent manner (Fig. 4A) . Compared with DMSO, Andro also inhibited growth and proliferation of Tb cells while inducing apoptosis in a dose-and time-dependent manner (Figs. 4B-4E ). Our results thus provide evidence for the inhibition of growth and the promotion of apoptosis of human squamous cell carcinoma through inactivation of NF-κB transcription factor p50.
DIscussIOn
Chemical induction of epithelial carcinogenesis in the buccal pouch of the Syrian hamster is a multistage model, which reiterates many features observed in human oral squamous cell carcinoma. This model has been widely used to test the efficacy of therapeutic agents, due mainly to easy accessibility for examination and follow-up of the oral lesions (Salley, 1954 ; Figure 1 . NF-κB activation during chemically induced squamous cell carcinogenesis. The H&E staining and the immunohistochemical staining of total p65, phosphorylated p65 (Ser536), and IκBα (pSer32/36) or c-Myc and cyclin D1 at the stages of normal, hyperplasia, dysplasia, carcinoma in situ, and carcinoma in DMBA-induced squamous cell carcinogenesis of the hamster buccal pouch. Results are representatives of at least 3 tissue samples from more than 3 hamsters for each group. Scale bars, 50 μm. Gimenez-Conti, 1993; . In the present study, we used this model and demonstrated that DMBA-induced squamous cell carcinogenesis induces NF-κB activation. Importantly, Andro abolished NF-κB activation and potently inhibited tumor growth, attesting to the causal roles of aberrant NF-κB activation during thepathogenesis of chemically induced oral squamous cell carcinoma. Our results indicate a potential clinical correlation of our experimental findings obtained in the chemically induced squamous cell carcinogenesis in the buccal pouch of hamsters. Consistently, NF-κB activation is known to be closely associated with tumorigenesis and metastasis (Loercher et al., 2004; Zhang et al., 2005; Allen et al., 2007) and sensitivity to chemotherapyand radiotherapy (Wang et al., 1999; Kato et al., 2000) and papilloma virus infection (Mishra et al., 2006) , and mastication of tobacco (Sawhney et al., 2007) triggers NF-κB activation in human oral squamous cell carcinoma. The aberrant activation of NF-κB transcription factors is known to regulate diverse pathological responses of carcinogenesis, including cell-cycle progression and proliferation, apoptosis, and angiogenesis (Deveraux et al., 1998; Li and Verma, 2002; Hayden and Ghosh, 2008) . Consistently, we found that Andro suppressed NF-κB activation for reduced expression of cyclin D1 and c-Myc and decreased BrdU incorporation, leading to inhibition of cell proliferation in vivo. In addition, Andro increased Tunel staining of DNA fragmentation for the induction of cell apoptosis in vivo through targeting p50 and abrogating NF-κB activation. Notably, Andro treatment also reduced microvessel density (MVD) in the cancerous tissues in vivo, suggesting that Andro inhibits angiogenesis during the pathogenesis of chemically induced oral squamous cell carcinoma. Notably, Andro is widely used in China as an over-the-counter medicine, which apparently has no serious complications or toxic effects reported in patients thus far. Taken together, the in vivo experimental findings that Andro significantly inhibits chemically induced oral squamous cell carcinogenesis suggest that the clinical merit for Andro treatment of squamous cell carcinoma warrants further investigation.
To dissect the molecular mechanisms of how inhibition of aberrant NF-κB activation translates into attenuation of chemically induced oral squamous cell carcinoma, we conducted in vitro experiments using the human tongue squamous cell carcinoma Tb cells. Consistent with a previous report (Yao et al., 2006) and our in vivo findings, treatment of Tb cells with Andro significantly decreased the phosphorylation of p65 (S536) and the expression of c-Myc and cyclin D1. Interestingly, Andro inhibited cell growth and induced cell apoptosis by arresting these squamous carcinoma cells at the G2/M stages in vitro. Importantly, our findings that Andro inhibits NF-κB activation for reduced p65 expression and phosphorylation and mitigated IκBα phosphorylation are fully consistent with those of previous reports (Jin et al., 2011; Kim et al., 2011) . Taken together, our results thus confirm that Andro inhibits tumor growth in vivo by the reduction of tumor cell proliferation, induction of tumor cell apoptosis, and suppression of tumor-induced angiogenesis through attenuation of aberrant NF-κB activation.
In summary, analysis of our experimental data suggests that NF-κB signaling plays a critical role during carcinogenesis of chemically induced hamster buccal pouch squamous cell carcinoma. Importantly, by targeting p50 and suppressing NF-κB activation, Andro potently attenuates chemically induced tumor growth for treating oral squamous cell carcinoma.
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